Neuroleptic Malignant Syndrome: A Review for Neurohospitalists

被引:132
作者
Berman, Brian D. [1 ]
机构
[1] Univ Colorado Denver, Sch Med, Dept Neurol, Acad Off 1,Mail Stop B-185,12631 East 17th Ave, Aurora, CO 80045 USA
关键词
neuroleptic malignant syndrome; movement disorders; neurohospitalist;
D O I
10.1177/1941875210386491
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neuroleptic malignant syndrome (NMS) is a life-threatening idiosyncratic reaction to antipsychotic drugs characterized by fever, altered mental status, muscle rigidity, and autonomic dysfunction. It has been associated with virtually all neuroleptics, including newer atypical antipsychotics, as well as a variety of other medications that affect central dopaminergic neurotransmission. Although uncommon, NMS remains a critical consideration in the differential diagnosis of patients presenting with fever and mental status changes because it requires prompt recognition to prevent significant morbidity and death. Treatment includes immediately stopping the offending agent and implementing supportive measures, as well as pharmacological interventions in more severe cases. Maintaining vigilant awareness of the clinical features of NMS to diagnose and treat the disorder early, however, remains the most important strategy by which physicians can keep mortality rates low and improve patient outcomes.
引用
收藏
页码:41 / 47
页数:7
相关论文
共 71 条
[1]   Tricyclics and malignant syndrome [J].
Abbar, M ;
Carlander, B ;
Castelnau, D .
EUROPEAN PSYCHIATRY, 1996, 11 (04) :212-213
[2]  
ADDONIZIO G, 1986, AM J PSYCHIAT, V143, P1587
[3]   Neuroleptic malignant syndrome [J].
Adnet, P ;
Lestavel, P ;
Krivosic-Horber, R .
BRITISH JOURNAL OF ANAESTHESIA, 2000, 85 (01) :129-135
[4]   Is risk of neuroleptic malignant syndrome increased in the postpartum period? [J].
Alexander, PJ ;
Thomas, RM ;
Das, A .
JOURNAL OF CLINICAL PSYCHIATRY, 1998, 59 (05) :254-255
[5]  
American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P739
[6]  
AYD F J Jr, 1956, J Clin Exp Psychopathol, V17, P189
[7]   Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: A case-control study [J].
Berardi, D ;
Amore, M ;
Keck, PE ;
Troia, M ;
Dell'Atti, M .
BIOLOGICAL PSYCHIATRY, 1998, 44 (08) :748-754
[8]   The evaluation and management of patients with neuroleptic malignant syndrome [J].
Bhanushali, MJ ;
Tuite, PJ .
NEUROLOGIC CLINICS, 2004, 22 (02) :389-+
[9]  
Birmes P, 2003, CAN MED ASSOC J, V168, P1439
[10]   NEUROLEPTIC MALIGNANT SYNDROME [J].
BUCKLEY, PF ;
HUTCHINSON, M .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1995, 58 (03) :271-273